Dermfree Wart Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of common warts. Common warts are characterized by their rough, 'cauliflower-like' surface appearance, making them easily identifiable.

Limitations of Use: This drug is specifically intended for the treatment of common warts and is not indicated for other types of warts or skin lesions.

Dosage and Administration

The affected area should be washed, and it is recommended to soak the wart in warm water for approximately 5 minutes. After soaking, the area must be dried thoroughly to ensure proper adhesion of the medicated plaster.

To apply the medicated patch, healthcare professionals should first remove the bandage strips by peeling the backing off. If necessary, the medicated patch may be cut to fit the size of the wart. The medicated plaster should then be applied carefully to the wart.

This procedure should be repeated every 48 hours as needed, continuing until the wart is removed, with a maximum treatment duration of up to 12 weeks.

Contraindications

Use is contraindicated in patients with the following conditions or situations:

Application is not recommended on irritated, infected, or reddened skin. The product should not be used on genital warts, facial warts, moles, birthmarks, or warts with hair growing from them. Additionally, it is contraindicated for use on mucous membranes.

Warnings and Precautions

For external use only. In the event of accidental ingestion, immediate medical assistance should be sought, or contact a Poison Control Center without delay.

This product must not be applied to irritated, infected, or reddened skin. It is contraindicated for use on genital warts, facial warts, moles, birthmarks, and any warts with hair growing from them. Additionally, application to mucous membranes is strictly prohibited.

Healthcare professionals should advise patients to consult a physician prior to use if they have a history of diabetes or poor blood circulation, as these conditions may increase the risk of adverse effects.

Side Effects

For external use only. Patients are advised to stop use and consult a doctor if they have diabetes or poor blood circulation prior to using the product. It is important for individuals with these conditions to seek medical advice before use to ensure safety and efficacy.

Drug Interactions

There are currently no documented drug interactions associated with this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Dermfree Wart Remover (salicylic acid 1% wart remover). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center is recommended.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

The available data regarding the use of this medication during pregnancy is limited. There are no specific safety concerns or dosage modifications outlined for pregnant patients. Additionally, no special precautions have been identified for women of childbearing potential. Healthcare professionals should consider the potential risks and benefits of treatment in pregnant patients, as well as the lack of comprehensive data on fetal outcomes. It is advisable to monitor any pregnant patients receiving this medication closely and to discuss the implications with them.

Lactation

There is no specific information available regarding the use of this medication in nursing mothers or its effects on lactation. Consequently, healthcare professionals should exercise caution when prescribing this medication to lactating mothers, as the potential risks to breastfed infants are not well characterized. It is advisable to consider the benefits of breastfeeding alongside the potential risks associated with the medication.

Renal Impairment

Patients with renal impairment may necessitate a reduced dose of the medication. It is essential for healthcare professionals to assess creatinine clearance prior to initiating therapy in this population. Regular renal function tests are recommended for patients with existing kidney problems to monitor their condition effectively. Additionally, special monitoring is required for patients with significant renal impairment to avoid potential toxicity associated with the medication.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

There is currently no specific information available regarding overdosage for this medication. In the absence of documented overdosage data, healthcare professionals are advised to exercise caution and monitor patients closely for any unusual symptoms or adverse effects that may arise following administration.

In the event of suspected overdosage, it is recommended that healthcare providers initiate supportive care and symptomatic treatment as necessary. Continuous monitoring of vital signs and clinical status is essential to ensure patient safety.

Healthcare professionals should also consider consulting a poison control center or relevant toxicology resources for guidance on management strategies tailored to the specific circumstances of the overdosage event.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information provided regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in question. Further studies may be necessary to fully evaluate the nonclinical toxicology profile.

Postmarketing Experience

No postmarketing experience details are available in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the medication is swallowed. It is crucial for patients to understand the importance of prompt action in such situations.

Additionally, healthcare providers should encourage patients to consult with their doctor prior to using the medication if they have a history of diabetes or poor blood circulation. This discussion is essential to ensure the safe and effective use of the medication, considering the potential risks associated with these conditions.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It is essential to store the product within a temperature range of 59° to 86°F (15° to 30°C) to maintain its integrity and efficacy. Proper storage conditions must be adhered to, ensuring that the product is kept in a suitable environment to prevent degradation.

Additional Clinical Information

Patients should wash the affected area by soaking the wart in warm water for 5 minutes and then drying the area thoroughly. Bandage strips should be removed by peeling the backing off, and if necessary, the medicated patch can be cut to fit the wart. This procedure may be repeated every 48 hours as needed until the wart is removed, for a maximum duration of 12 weeks.

Clinicians should advise patients to consult a doctor before use if they have diabetes or poor blood circulation. No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.